- Home
- FBLG vs CELU Comparison
FBLG vs CELU Comparison
Compare FBLG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBLG
- CELU
- Stock Information
- Founded
- FBLG 2021
- CELU 2016
- Country
- FBLG United States
- CELU United States
- Employees
- FBLG N/A
- CELU N/A
- Industry
- FBLG
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- FBLG
- CELU Health Care
- Exchange
- FBLG NYSE
- CELU Nasdaq
- Market Cap
- FBLG 37.1M
- CELU 37.7M
- IPO Year
- FBLG 2024
- CELU N/A
- Fundamental
- Price
- FBLG $0.85
- CELU $2.06
- Analyst Decision
- FBLG Strong Buy
- CELU
- Analyst Count
- FBLG 4
- CELU 0
- Target Price
- FBLG $13.00
- CELU N/A
- AVG Volume (30 Days)
- FBLG 222.2K
- CELU 97.6K
- Earning Date
- FBLG 05-14-2025
- CELU 05-08-2025
- Dividend Yield
- FBLG N/A
- CELU N/A
- EPS Growth
- FBLG N/A
- CELU N/A
- EPS
- FBLG N/A
- CELU N/A
- Revenue
- FBLG N/A
- CELU $54,220,000.00
- Revenue This Year
- FBLG N/A
- CELU $23.29
- Revenue Next Year
- FBLG N/A
- CELU N/A
- P/E Ratio
- FBLG N/A
- CELU N/A
- Revenue Growth
- FBLG N/A
- CELU 138.11
- 52 Week Low
- FBLG $0.70
- CELU $1.00
- 52 Week High
- FBLG $11.75
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- FBLG 46.98
- CELU 51.00
- Support Level
- FBLG $0.70
- CELU $1.90
- Resistance Level
- FBLG $0.94
- CELU $2.40
- Average True Range (ATR)
- FBLG 0.09
- CELU 0.25
- MACD
- FBLG 0.00
- CELU -0.02
- Stochastic Oscillator
- FBLG 34.69
- CELU 24.76
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.